Topical immune activator: A potential modality for skin cancer treatment

Reactivation of the immune system may be a potent therapy option for skin cancer treatment. We investigate how tumor exposure to dermatological lasers, including ablative fractional laser, activate an immune response intratumorally and assess efficacy of the treatment alone and in combination with immunotherapy. We have thus shown that ablative fractional laser in combination with topical imiquimod may be a potential treatment for actinic keratoses and squamous cell carcinoma.